Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus

Terminated

• Conditions: Adenocarcinoma Esophagus

• Registration Number: NCT02991547
• Lead Sponsor: The Guthrie Clinic

Brief Summary

The purpose of this study is to find out more information about patients who have cancer (adenocarcinoma) of the esophagus or gastroesophageal junction (GEJ) who have been treated with chemotherapy and radiation but have not had surgery. The study will follow patients for 5 years to monitor for their cancer and to see how the standard medical care affects the daily life of patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-11-28
• Study Start: 2016-12
• Study First Submitted QC: 2016-12-09
• Study First Posted: 2016-12-13
• Primary Completion: 2018-08-03
• Study Completion: 2018-08-03
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-09
• Last Update Posted: 2024-02-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• Adenocarcinoma of esophagus or gastroesophageal junction (nidus of the cancer within 5 cm from the gastroesophageal junction) confirmed by biopsy with clinical stage I, II, or III. The superficial adenocarcinoma of the esophagus will be excluded.

• Received no previous treatment for esophageal cancer.

• Measurable or evaluable disease

• ECOG performance status: 0 to 2 that is able to perform activities of daily living with minimal assistance

• Adequate bone marrow function (hemoglobulin ≥8 g/dl, neutrophil ≥1.5x109/L and platelet ( ≥100x109/L)

• Adequate liver function

  • Bilirubin normal, Meets 1 of the following criteria:
  • Alkaline phosphatase (AP) normal AND AST/ALT ≤ 5 times upper limit of normal (ULN)
  • AP ≤ 2.5 times ULN AND AST/ALT ≤ 1.5 times ULN
  • AP ≤ 5 times ULN AND AST/ALT normal

• Adequate kidney function (creatinine ≤1.5 UNL and creatinine clearance ≥ 60 )

• Be at least 4 weeks from recent major surgical procedures.

• Patients must be able to understand the nature of the study and give written informed consent

• At least one measurable lesion on CT, MRI or esophageal barium exam.

Exclusion Criteria

• Age < 18 years and >80 years
• Contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or hematemesis
• Participating in other clinical trials
• Pregnancy
• Clinically significant and uncontrolled major medical conditions including but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements
• any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression free survival	5 years

Secondary Outcome Measures

Name	Time	Method
Adverse effect profile	5 years
Overall survival	5 years
Occurrence of local recurrence or mestastasis or both	5 years
Rate of complete remission	8 weeks after completion of neoadjuvant chemoradiotherapy

Trial Locations

Locations (2)

Guthrie Corning Hospital; 🇺🇸 Corning, New York, United States

Guthrie Medical Group, PC/Robert Packer Hospital; 🇺🇸 Sayre, Pennsylvania, United States